Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring最新文献

{"title":"Proteomic profiling identifies serpin G1, ApoA-II, and LBP as potential biomarkers of dementia in an Egyptian cohort.","authors":"Shimaa A Heikal, Eman M Khedr, Mai Othman, Nesma G Elsheikh, Heba M Tawfik, Hany I Hassanin, Nouran Al-Shehaby, Ashraf Eltaher, Samir Shamma, Ahmed S Mohamed, Mostafa Saber, Abdullah A Lomomba, Esraa Ali, Shady M Safwat, Noha Abo Elfetoh, Gharib Fawi, Noha A Yousri, Mohamed Salama","doi":"10.1002/dad2.70172","DOIUrl":"10.1002/dad2.70172","url":null,"abstract":"<p><strong>Background: </strong>Dementia, including Alzheimer's disease (AD), is a growing concern in Egypt, yet biomarker research in this population is scarce. Identifying serum biomarkers is essential for early diagnosis and understanding disease mechanisms in underrepresented groups.</p><p><strong>Methods: </strong>We performed serum proteomic profiling on 20 Egyptian dementia patients and 10 cognitively unimpaired controls from the Egyptian Dementia Registry using mass spectrometry. Differential protein expression and pathway enrichment analyses were conducted.</p><p><strong>Results: </strong>Of 260 quantified proteins, 21 were significantly different between dementia patients and controls (<i>P</i> < 0.05). Several serine protease inhibitor and immunoglobulin family proteins were downregulated, while apolipoprotein A-II was upregulated in dementia. Enrichment analysis revealed associations with inflammation, complement activation, and lipid metabolism pathways.</p><p><strong>Conclusion: </strong>This is the first serum proteomic study of dementia in an Egyptian cohort, highlighting coordinated changes in protein families involved in inflammation and lipid metabolism, and emphasizing the importance of biomarker research in diverse populations.</p><p><strong>Highlights: </strong>The study presents initial proteomic data from the Egyptian Dementia Registry.The Egyptian population has been underrepresented in the area of dementia research.Serine protease inhibitor G1, apolipoprotein A-II, and lipopolysaccharide binding protein emerged as significant proteins.The work lays the foundation for more understanding of molecular determinants in dementia in the Middle East.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70172"},"PeriodicalIF":4.4,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.","authors":"Doris P Molina-Henry, Rema Raman, Andy Liu, Oliver Langford, Joel B Braunstein, Philip B Verghese, Venky Venkatesh, Shobha Dhadda, Michael Irrizary, Joshua D Grill, Keith Johnson, Robert A Rissman, Paul Aisen, Reisa A Sperling","doi":"10.1002/dad2.70164","DOIUrl":"10.1002/dad2.70164","url":null,"abstract":"<p><strong>Introduction: </strong>Consistent predictive performance across racial and ethnic groups is essential to the use of plasma biomarkers as screening tools in preclinical Alzheimer's disease trials.</p><p><strong>Methods: </strong>Logistic regression examined racial and ethnic group differences in plasma eligibility using an algorithm that included Phosphorylated tau217 to non-phosphorylated tau217 ratio, amyloid beta 42/40, age, and apolipoprotein E to predict > 18 Centiloids on amyloid imaging in cognitively unimpaired individuals.</p><p><strong>Results: </strong>Among 6437 participants screened, with non-Hispanic (NH) White as the reference group, odds ratios of plasma ineligibility were 2.88 (95% confidence interval [CI]: 1.40-6.96) for Hispanic Black, 1.60 (95% CI: 1.33-1.92) for Hispanic White, 2.10 (95% CI: 1.37-3.38) for NH Asian, and 1.59 (95% CI: 1.27-2.0) for NH Black participants. Positron emission tomography (PET) eligibility rates did not differ among those who were plasma eligible.</p><p><strong>Discussion: </strong>Differential rates of plasma eligibility, but consistent PET eligibility among plasma-eligible participants, were observed, supporting the use of universal biomarker cutpoints across race and ethnic groups.<b>Highlights:</b> Underrepresented racial and ethnic groups had lower rates of plasma eligibility compared to non-Hispanic White individuals based on a plasma screening algorithm that included the phosphorylated tau 217 ratio.Among plasma-eligible participants, amyloid positron emission tomography eligibility rates did not differ by racial and ethnic group.Plasma biomarker tests may provide equivalent effectiveness for identifying imaging biomarker eligible, cognitively unimpaired individuals across racial and ethnic groups.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70164"},"PeriodicalIF":4.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships among young adult general cognitive ability, midlife physical activity, and early late-life cognitive functioning: A four-decade longitudinal cohort study in men.","authors":"Paula Iso-Markku, Erik J Buchholz, Xin M Tu, Nathan Gillespie, Chandra A Reynolds, Michael J Lyons, William S Kremen, Carol E Franz","doi":"10.1002/dad2.70169","DOIUrl":"10.1002/dad2.70169","url":null,"abstract":"<p><strong>Introduction: </strong>Research on whether physical activity (PA) is associated with cognition is abundant but very few studies have examined the extent to which prior cognitive ability may account for PA participation in midlife.</p><p><strong>Methods: </strong>Over 800 men self-reported PA at average ages of 40 and 56. General cognitive ability (GCA) was assessed at an average age of 20. Specific cognitive abilities and GCA were assessed at average ages of 56 and 68. Relationships among age 20 GCA, midlife PA, and cognitive functioning in mid- and late-life were examined with generalized estimating equations.</p><p><strong>Results: </strong>Age 20 GCA was significantly associated with age 56 leisure metabolic equivalent of energy expenditure (MET)-hours of PA (<i>b</i> = 0.14, <i>p</i> = 0.027). Age 56 leisure MET-hours were positively (<i>b</i> = 0.04, <i>p</i> = 0.021) and age 40 vigorous leisure PA was inversely (<i>b</i> = -0.10, <i>p</i> = 0.012) associated with age 68 GCA (<i>b</i> = 0.04, <i>p</i> = 0.021).</p><p><strong>Discussion: </strong>There are reciprocal associations between PA and cognitive functioning.</p><p><strong>Highlights: </strong>Young adult general cognitive ability (GCA) predicts midlife physical activity (PA).Midlife PA and cognition were not associated after adjusting for young adult GCA.Midlife PA is associated with later-life cognition, adjusted for young adult GCA.Work-related PA was inversely associated with later-life cognitive functioning.The relationship between PA and cognitive function is bidirectional.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70169"},"PeriodicalIF":4.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of cognitive reserve in white matter hyperintensities: from cognitive aging to Alzheimer's spectrum.","authors":"Yu-Ruei Lin, Wei-Lu Lee, Jong-Ling Fuh","doi":"10.1002/dad2.70167","DOIUrl":"10.1002/dad2.70167","url":null,"abstract":"<p><strong>Introduction: </strong>White matter hyperintensities (WMHs) are characteristic of Alzheimer's disease (AD), and cognitive reserve (CR) protects cognitive function. However, whether WMHs mediate the CR-cognition relationship remains unclear.</p><p><strong>Methods: </strong>Brain imaging, clinical features, and neuropsychological assessments were performed, and CR was measured using the Cognitive Reserve Index questionnaire. Bootstrap mediation analysis examined CR's role in specific cognitive functions, controlling for covariates.</p><p><strong>Results: </strong>Participants who were cognitively unimpaired (CU; <i>n</i> = 85, mean age = 68.6 ± 5.7) and who had mild cognitive impairment (MCI; <i>n</i> = 43, mean age = 71.8 ± 6.5) or AD (<i>n</i> = 61, mean age = 72.8 ± 6.2) were included. CR was positively associated with global and non-memory cognitive functions in the CU and MCI groups. In the CU group, WMHs served as a mediator between CR and global cognitive ability.</p><p><strong>Discussion: </strong>CR may maintain the optimal cognitive function by mitigating the WMH burden independently of AD-related brain changes.</p><p><strong>Highlights: </strong>Cognitive reserve (CR) positively links to non-memory cognition.Cognitive reserve mitigates white matter hyperintensities to preserve cognition.Cognitive reserve primarily protects cognition in pre-Alzheimer's stages.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70167"},"PeriodicalIF":4.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mobile Toolbox for remote, self-administered cognitive assessment in older adults: associations with in-clinic cognitive testing and Alzheimer's disease biomarkers.","authors":"Roos J Jutten, Jessa E Burling, Elliott Slade, Jackson C Thompson, Jessie Fanglu Fu, Colin Birkenbihl, Michael J Properzi, Gad A Marshall, Rebecca E Amariglio, Kathryn V Papp, Keith A Johnson, Julie C Price, Reisa A Sperling, Dorene M Rentz","doi":"10.1002/dad2.70160","DOIUrl":"10.1002/dad2.70160","url":null,"abstract":"<p><strong>Introduction: </strong>Remote, smartphone-based cognitive assessments such as the Mobile Toolbox (MTB) may increase the accessibility of Alzheimer's disease (AD) clinical trials. We examined the feasibility of the MTB among cognitively unimpaired (CU) older adults and investigated its associations with standardized in-clinic cognitive testing and amyloid and tau positron emission tomography imaging.</p><p><strong>Methods: </strong>A total of 100 CU older adults self-administered the MTB remotely on their personal devices. Linear regression models correcting for demographics investigated associations of MTB fluid and crystallized cognition composites with in-clinic Preclinical Alzheimer's Cognitive Composite-5 (PACC-5) scores, global amyloid-beta burden and tau deposition in the medial-temporal lobe and neocortex.</p><p><strong>Results: </strong>Most participants completed the MTB without requiring assistance (81%) or reminders (61%). MTB fluid cognition scores were positively associated with PACC-5 scores and negatively with tau deposition in the medial-temporal lobe and neocortex.</p><p><strong>Discussion: </strong>These findings suggest that the MTB may provide a feasible approach to capture cognitive processes relevant in preclinical AD.</p><p><strong>Highlights: </strong>The Mobile Toolbox (MTB) is a remote smartphone-based cognitive assessment.We deployed the MTB in CU older adults with Alzheimer's disease (AD) biomarkers.We show how the MTB may facilitate cognitive assessment in preclinical AD research.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70160"},"PeriodicalIF":4.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Day-to-day sleep efficiency and driving behaviors in older adults with and without cognitive impairment.","authors":"Jun Ha Chang, Yunwen Huang, Ying Zhang, Su Chen, Daniel L Murman, Vaishali Phatak, Matthew Rizzo","doi":"10.1002/dad2.70173","DOIUrl":"10.1002/dad2.70173","url":null,"abstract":"<p><strong>Introduction: </strong>Sleep disturbances are common in older adults, particularly those with cognitive impairment. This study examines how day-to-day sleep quality impacts real-world driving behaviors, offering insight into sleep as a potential functional biomarker of cognitive health.</p><p><strong>Methods: </strong>We monitored 149 community-dwelling older adults (90 cognitively impaired, 59 unimpaired) over 12 weeks. Sleep was measured via wrist-worn actigraphy, and driving data were collected via an in-vehicle sensor system. A zero-inflated Poisson regression model examined whether sleep efficiency was associated with next-day driving likelihood and frequency, and whether these relationships varied by cognitive status.</p><p><strong>Results: </strong>Better sleep efficiency increased the likelihood of driving the next day more for cognitively impaired participants than for unimpaired participants. Higher sleep efficiency was associated with increased driving frequency in both groups.</p><p><strong>Discussion: </strong>These findings underscore the importance of daily sleep variability as a potential digital biomarker for functional abilities in older adults, highlighting opportunities for early intervention to preserve mobility and independence.</p><p><strong>Highlights: </strong>A 1 standard deviation increase in sleep efficiency increases next-day trip counts (incidence rate ratio = 1.014).In cognitively impaired participants, better sleep lowers the odds of not driving the next day (odds ratio = 0.877).Among those who choose to drive, trip counts do not differ by cognitive status.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70173"},"PeriodicalIF":4.4,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and blood-based biomarkers of neurodegeneration in community dwelling Australians from ISLAND (Island Study Linking Ageing and Neurodegenerative Disease).","authors":"Eddy Roccati, Jessica Marie Collins, Michele Linda Callisaya, Jane Elizabeth Alty, Anna Elizabeth King, James John Rochfort Brady, James Clement Vickers","doi":"10.1002/dad2.70166","DOIUrl":"10.1002/dad2.70166","url":null,"abstract":"<p><strong>Introduction: </strong>Physical activity, a key modifiable risk factor for dementia, has been associated with biomarkers of neurodegeneration in the central nervous system, but less is known regarding blood-based biomarkers.</p><p><strong>Methods: </strong>A total of 739 cognitively healthy participants (aged 50-83 years) from ISLAND (Island Study Linking Ageing and Neurodegenerative Disease) completed a battery of online surveys. Self-reported physical activity was assessed based on daily metabolic equivalent, and a blood sample was analyzed for serum neurofilament light chain, serum glial fibrillary acidic protein (GFAP), plasma phosphorylated tau, and genotyped for apolipoprotein E (<i>APOE</i>) ε4.</p><p><strong>Results: </strong>Higher self-reported physical activity was significantly associated with lower log-transformed concentrations of GFAP (pg/mL, <i>β</i> = -0.022, <i>P</i> = 0.009) in fully adjusted generalized linear regression models. Subgroup analysis revealed this association was only significant in <i>APOE</i> ε4 non-carriers.</p><p><strong>Discussion: </strong>This cross-sectional study provides novel evidence for the association of physical activity with blood-based biomarkers of neurodegeneration, and how <i>APOE</i> ε4 presence modifies this relationship.</p><p><strong>Highlights: </strong>We looked at a large-scale (<i>n</i> = 739) community cohort of healthy Australians > 50 years of age.Physical activity (PA) levels were related to blood-based biomarkers of neurodegeneration.Higher PA was associated with lower serum glial fibrillary acidic protein (GFAP).Apolipoprotein E ε4 and PA intensity impacted this association.This novel finding provides a foundation for targeted physical activity interventions.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70166"},"PeriodicalIF":4.4,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower odor identification in subjective cognitive decline: a meta-analysis.","authors":"Benoît Jobin, Zigrand Coline, Johannes Frasnelli, Benjamin Boller, Mark W Albers","doi":"10.1002/dad2.70168","DOIUrl":"10.1002/dad2.70168","url":null,"abstract":"<p><strong>Introduction: </strong>Odor identification correlates with Alzheimer's disease (AD) biomarkers, and its decline may emerge before measurable cognitive deficits - as early as the subjective cognitive decline (SCD) stage. We aimed to compare odor identification between SCD and cognitively normal (CN) stages.</p><p><strong>Methods: </strong>A systematic search of four databases identified studies assessing olfactory identification and cognitive screening in individuals aged 50+. A random-effects meta-analysis was performed on 11 studies (660 SCD, 574 CN).</p><p><strong>Results: </strong>Individuals with SCD exhibited lower olfactory identification scores compared to CN participants (SMD = -0.67, 95% CI [-1.31, -0.03], <i>p</i> = 0.04). Meta-regression revealed a negative association (<i>β</i> = -1.79, <i>p</i> = 0.02) between cognitive and olfactory differences; lower olfactory identification scores in SCD occurred despite minimal cognitive differences across groups.</p><p><strong>Discussion: </strong>Odor identification is lower in pre-mild cognitive impairment individuals reporting SCD. Olfactory decline may emerge prior to measurable general cognitive decline, supporting its role as a screen for AD.</p><p><strong>Highlights: </strong>Individuals with SCD exhibit lower odor identification scores.Olfactory identification may serve as an early marker of neurodegeneration in preclinical AD.Heterogeneity highlights the need for multimodal biomarker approaches.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70168"},"PeriodicalIF":4.4,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classifying mild cognitive impairment from normal cognition: fMRI complexity matches tau PET performance.","authors":"Kay Jann, Gilsoon Park, John M Ringman, Hosung Kim","doi":"10.1002/dad2.70159","DOIUrl":"10.1002/dad2.70159","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive decline in Alzheimer's disease (AD) is closely linked to tau pathology, which leads to loss of synaptic connections and ultimately neurons. While tau positron emission tomography (PET) carries radiation risks, is costly, and often unavailable in clinical settings, brain entropy mapping via resting-state functional magnetic resonance imaging (fMRI) has emerged as a marker of impaired brain function related to tauopathy.</p><p><strong>Methods: </strong>Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Estudio de la Enfermedad de Alzheimer en Jalisciences (EEAJ), we investigate the classification performance of fMRI entropy with tau PET in distinguishing cognitively normal (CN) from cognitively impaired (mild cognitive impairment/AD) individuals. Convolutional neural networks, initially trained and evaluated via 5-fold cross-validation on ADNI data, were subsequently tested on an independent external cohort (EEAJ) using an ensemble approach.</p><p><strong>Results: </strong>The fMRI entropy classifier matched the tau PET model in accuracy and outperformed it in F1 score (0.64 vs. 0.61) and area under the curve (AUC; 0.73 vs. 0.67). On the independent external validation dataset (EEAJ), fMRI sample entropy showed a comparable F1 score (0.88) to tau PET (0.88) and achieved a notably higher AUC (0.94 vs. 0.92).</p><p><strong>Discussion: </strong>Our findings suggest that fMRI entropy could be a non-invasive imaging marker alternative to tau PET for detecting AD-related cognitive impairment.</p><p><strong>Highlights: </strong>Functional magnetic resonance imaging (fMRI) complexity matches tau positron emission tomography (PET) in classifying cognitive impairment.Sample entropy and multiscale entropy were used for fMRI-based Alzheimer's disease (AD) classification.3D convolutional neural networks models achieve up to 84% accuracy using fMRI complexity measures.The dorsal attention network was identified as critical for distinguishing mild cognitive impairment/AD.fMRI complexity offers a non-invasive alternative to tau positron emission tomography imaging.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70159"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of two clinical Centiloid analysis products for ¹⁸F-florbetapir PET in cognitively unimpaired elders.","authors":"Frank P DiFilippo, Stephen M Rao","doi":"10.1002/dad2.70163","DOIUrl":"10.1002/dad2.70163","url":null,"abstract":"<p><strong>Introduction: </strong>Recently two software products (MIMneuro and Syngo.PET) received United States Food and Drug Administration (FDA) clearance for Centiloid analysis, thereby introducing Centiloid scoring to the clinical environment. This study compares Centiloid scores by these clinical products and conventional research methods.</p><p><strong>Methods: </strong>¹⁸F-Florbetapir amyloid positron emission tomography (PET) scans (<i>N </i>= 252) of cognitively unimpaired elders were processed using both products and using research pipelines based on the Standard Centiloid method (magnetic resonance imaging [MRI]-based spatial normalization).</p><p><strong>Results: </strong>Centiloid scores from both products were highly linearly correlated with each other (<i>r²</i> = 0.942) and with an MRI-based research pipeline having matching regions of interest (MIMneuro: <i>r²</i> = 0.942, Syngo.PET: <i>r²</i> = 0.971). However, Centiloid scores often differed by more than 10 Centiloids [CL] between methods, with Centiloid calibrations contributing to their inconsistency.</p><p><strong>Discussion: </strong>Although Centiloid analyses were highly correlated, there was considerable variability in individual cases. Other factors not investigated (e.g., radiopharmaceutical, uptake time) could further contribute to variability. Clinicians should use caution when considering thresholds for amyloid positivity in individual cases.</p><p><strong>Highlights: </strong>Two newly available clinical software products, which provide rapid and simple Centiloid scoring, are compared to research processing involving both PET and MRI images.Excellent linear correlations were found among the methods.Centiloid scores for individual cases often differed by more than 10CL, which should be taken into consideration in clinical reporting.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70163"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}